Literature DB >> 26091250

The Treatment Acceptability/Adherence Scale: Moving Beyond the Assessment of Treatment Effectiveness.

Irena Milosevic1,2, Hannah C Levy3, Gillian M Alcolado3, Adam S Radomsky3.   

Abstract

It is becoming more broadly recognized that beyond effectiveness, the acceptability of interventions for anxiety disorders is an important consideration for evidence-based practice. Although advances in treatments for anxious psychopathologies have demonstrated that cognitive-behavioural interventions are more desirable than other types of psychotherapy or pharmacotherapy, there continue to be problems with adherence and dropout. It has been suggested that low treatment acceptability may be partially responsible for high dropout rates. Although a number of preliminary investigations in this domain have been conducted, further progress is hampered by the absence of a single self-report measure that assesses both acceptability and anticipated adherence. Therefore, the current paper aimed to test the psychometric properties of the newly developed Treatment Acceptability/Adherence Scale (TAAS). In two studies of brief cognitive-behavioural interventions, the TAAS was administered immediately following the therapy session. In Study 1 (N = 120 non-clinical undergraduates), the therapy included two variants of an exposure-based intervention for contamination fear. In Study 2 (N = 27 individuals with obsessive-compulsive disorder), the therapy was a cognitively based intervention evaluating a novel treatment technique for checking compulsions. Measures of convergent and divergent validity were included. Results demonstrated that the TAAS exhibited sound psychometric properties across the two samples. It is hoped that this measure will help clinicians to predict and intervene when a treatment is not acceptable and/or when the client anticipates poor adherence to it. Furthermore, the TAAS may aid researchers in continuing to improve upon effective interventions for anxiety and related disorders.

Entities:  

Keywords:  CBT; acceptability; adherence; anxiety; scale development

Mesh:

Year:  2015        PMID: 26091250     DOI: 10.1080/16506073.2015.1053407

Source DB:  PubMed          Journal:  Cogn Behav Ther        ISSN: 1650-6073


  16 in total

1.  Acceptability of mindfulness-based interventions for substance use disorder: A systematic review.

Authors:  Tara Bautista; Dara James; Hortensia Amaro
Journal:  Complement Ther Clin Pract       Date:  2019-02-20       Impact factor: 2.446

2.  The Appalachia Mind Health Initiative (AMHI): a pragmatic randomized clinical trial of adjunctive internet-based cognitive behavior therapy for treating major depressive disorder among primary care patients.

Authors:  Robert M Bossarte; Ronald C Kessler; Andrew A Nierenberg; Ambarish Chattopadhyay; Pim Cuijpers; Angel Enrique; Phyllis M Foxworth; Sarah M Gildea; Bea Herbeck Belnap; Marc W Haut; Kari B Law; William D Lewis; Howard Liu; Alexander R Luedtke; Wilfred R Pigeon; Larry A Rhodes; Derek Richards; Bruce L Rollman; Nancy A Sampson; Cara M Stokes; John Torous; Tyler D Webb; Jose R Zubizarreta
Journal:  Trials       Date:  2022-06-20       Impact factor: 2.728

3.  The Ohio State University Early Psychosis Intervention Center (EPICENTER) step-based care programme for individuals at clinical high risk for psychosis: study protocol for an observational study.

Authors:  Nicholas J K Breitborde; Hossam Guirgis; Walter Stearns; Kristen M Carpenter; Ghada Lteif; Jacob G Pine; Nichole Storey; Heather Wastler; Aubrey M Moe
Journal:  BMJ Open       Date:  2020-01-27       Impact factor: 2.692

4.  Effectiveness and acceptability of cognitive-behavioural therapy based interventions for maternal peripartum depression: a systematic review, meta-analysis and thematic synthesis protocol.

Authors:  Danelle Pettman; Heather O'Mahen; Agneta Skoog Svanberg; Louise von Essen; Cathrine Axfors; Oscar Blomberg; Joanne Woodford
Journal:  BMJ Open       Date:  2019-12-22       Impact factor: 2.692

5.  Effects of e-aid cognitive behavioural therapy for insomnia (eCBTI) to prevent the transition from acute insomnia to chronic insomnia: study protocol for a randomised controlled trial.

Authors:  Yuan Yang; Xian Luo; Dhirendra Paudel; Jihui Zhang; Shirley Xin Li; Bin Zhang
Journal:  BMJ Open       Date:  2019-11-18       Impact factor: 2.692

6.  Exploring Perceptions of Internet-Delivered Cognitive Behaviour Therapy among Public Safety Personnel: Informing Dissemination Efforts.

Authors:  Hugh C McCall; Angelo P Sison; Jody L Burnett; Janine D Beahm; Heather D Hadjistavropoulos
Journal:  Int J Environ Res Public Health       Date:  2020-08-19       Impact factor: 3.390

7.  Evaluation of a Mobile App to Enhance Relational Awareness and Change During Cognitive Analytic Therapy: Mixed Methods Case Series.

Authors:  Stephen Kellett; Katherine Easton; Martin Cooper; Abigail Millings; Melanie Simmonds-Buckley; Glenys Parry
Journal:  JMIR Ment Health       Date:  2020-12-18

8.  Acceptability of intravitreal injections in geographic atrophy: protocol for a mixed-methods pilot study.

Authors:  Jamie Enoch; Arevik Ghulakhszian; David P Crabb; Christiana Dinah; Deanna J Taylor
Journal:  BMJ Open       Date:  2021-04-24       Impact factor: 2.692

9.  Amplification of Positivity Therapy for Co-occurring Alcohol Use Disorder with Depression and Anxiety Symptoms: Pilot Feasibility Study and Case Series.

Authors:  Elisabeth Akeman; Evan White; Kate Wolitzky-Taylor; Jessica Santiago; Timothy J McDermott; Danielle C DeVille; Jennifer L Stewart; Martin Paulus; Charles T Taylor; Robin L Aupperle
Journal:  Behav Modif       Date:  2021-07-12

10.  Eye movement desensitization and reprocessing (EMDR) therapy for posttraumatic stress disorder in adults with serious mental illness within forensic and rehabilitation services: a study protocol for a randomized controlled trial.

Authors:  Susanna Every-Palmer; Tom Flewett; Shaystah Dean; Oliver Hansby; Atalie Colman; Mark Weatherall; Elliot Bell
Journal:  Trials       Date:  2019-11-21       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.